Medicines A-to-Z

Medicines A–Z

Drug name	NICE TAs	Comments
Enfortumab vedotin (Padcev®)		NICE TA 1097 Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable \| Guidance \| NICE
Enoxaparin Injection		For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. However, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain red (ESCAs to be developed).
Entacapone tablets
Entrectinib	TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide capsules	TA377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide capsules#8.3	TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer	For hospital use only
Eosin solution 2% w/v		Unlicensed special
Epaderm ointment
Ephedrine injection		Hospital use only
Ephedrine nose drops 0.5% and 1% drops		Short term use only